2篇
您的检索式：作者名="Luisa Pasulo"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Management of hepatitis C infection before and after liver transplantation显示文摘Chronic hepatitis C(CHC) is the most common indication for liver transplantation(LT). Aggressive treatment of hepatitis C virus(HCV) infection before cirrhosis development or decompensation may reduce LT need and risk of HCV recurrence post-LT. Factors associated with increased HCV risk or severity of recurrence include older age, immunosuppression, HCV genotype 1 and high viral load at LT. HCV recurrence post-LT leads to accelerated liver disease and cirrhosis development with reduced graft and patient survival. Currently, interferon(IFN)-based regimens can be used in dualagent regimens with ribavirin, in triple-agent antiviral strategies with direct-acting antivirals(e.g., protease inhibitors telaprevir or boceprevir), or before transplant in compensated patients to reduce HCV viral load to prevent or reduce the risk of post-LT recurrence and complications; they cannot be used in patients with decompensated cirrhosis. IFN-based regimens are used in less than half of HCV-infected patients waiting for LT due to extremely low efficacy and poor tolerability. However, antiviral therapy is indicated after LT in patients with histologically confirmed CHC despite tolerability issues. Improvements in side effect management have increased survival in patients achieving therapeutic targets. HCV treatment pre- and post-LT results in significant health care costs especially when lack of efficacy leads to disease worsening, although studies have shown sofosbuvir treatment before LT vs conventional post-LT dual antiviral is cost effective. The suboptimal efficacy and tolerability of IFN-based therapies, plus the significant economic burden, means the need for effective and well tolerated IFN-free antiHCV therapy for pre- and post-LT remains high. | Stefano Fagiuoli Roberto Ravasio Maria Grazia Lucà Anna Baldan Silvia Pecere Alessandro Vitale Luisa Pasulo | 2015 | World Journal of Gastroenterology2015，21，15： | 1 |
| 2 | Treatment of genotype‐1 hepatitis C recurrence after liver transplant improves survival in both sustained responders and relapsers显示文摘 | Francesca Romana Ponziani Alessandro Milani Antonio Gasbarrini Raffaella Zaccaria Raffaella Viganò Rosa Maria Iemmolo Maria Francesca Donato Maria Rendina Pierluigi Toniutto Luisa Pasulo Matteo Cescon Patrizia Burra Lucia Miglioresi Manuela Merli Daniele | 2012 | Transpl Int2012，，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员